NG25

SKU: orb1301625

Description

NG25 is a potent and selective small molecule inhibitor targeting both TAK1 and MAP4K2, with respective IC50 values of 149 nM and 21.7 nM. This compound is a valuable research tool for investigating inflammatory and oncogenic signaling pathways in both cellular and animal models.

Research Area

Signal Transduction

Key Properties

• CAS Number: 1315355-93-1
• MW: 537.58
• Purity: 99.79% (May vary between batches)
• Formula: C₂₉H₃₀F₃N₅O₂
• SMILES: CCN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(Oc4ccnc5[nH]ccc45)c3)cc2C(F)(F)F)CC1
• Target: MAPK
• Solubility: DMSO:16.67 mg/mL (31.01 mM);10% DMSO+40% PEG300+5% Tween 80+45% Saline:2 mg/mL (3.72 mM)

Bioactivity

• Target IC50:
  Raf-1:7590 nM|TAK1:149 nM|SRC:113 nM|ZAK:698 nM|ZC1/HGK:3250 nM|Lyn:12.9 nM|MAP4K2:21.7 nM|GSK:56.4 nM|Abl/Arg:75.2 nM|EphB4:999 nM|EphA2:773 nM|FER:82.3 nM|EphB2:672 nM
  Read more...
• In Vitro:
  NG25 sensitizes the breast cancer cells to Dox treatment in vitro. This combination may be an effective and feasible therapeutic option maximizing Dox efficacy and meanwhile minimizing Dox side effects in treating breast cancer.
  Read more...
• Cell Research:
  Breast cancer cells were seeded in 12-well plates at 2 × 10^3 cells per well, then incubated with Dox alone or Dox with NG25 at indicated concentrations after 72 h and then were cultured in fresh medium without drug. Two weeks later, cells were fixed and stained with methanol/crystal violet for 10 min, and photographed. Each experiment was performed in triplicates.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

MAP4K, MAP4K2/TAK1, MAP3K, MAPK Kinase Kinase Kinase, MAP kinase kinase kinase, MEKK, MAPKKK, Inhibitor, NG 25, NG25, NG-25, inhibit

Compound Identifiers

PubChem CID

53340664